As of November 6, 2026, Phathom Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: PHAT). The largest holder reporting an active stake on Schedule 13D is Frazier Life Sciences Public Fund, L.P., at 7.4%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (5.5%) (Schedule 13D/A, November 2, 2026).
Is this your company?
About to sign with, pay or invest in Phathom Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Phathom Pharmaceuticals, Inc. a real, registered company?
- Phathom Pharmaceuticals, Inc. files with the SEC under CIK 1783183 (its SEC filings).
- Its shares are listed under the ticker PHAT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Florham Park, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PHATHOM PHARMACEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Frazier Life Sciences Public Fund, L.P. (filed 2026-11-02).
Who are Phathom Pharmaceuticals, Inc.'s owners and officers?
Phathom Pharmaceuticals, Inc.: incorporated in Delaware; business address in Florham Park, New Jersey; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-02 | Frazier Life Sciences Public Fund, L.P. | 7.4% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.5% |
| Schedule 13G/A, 2026-07-20 | Millennium Management LLC | 4.2% |
| Schedule 13G, 2026-03-12 | Millennium Management LLC | 5.3% |
| Schedule 13G/A, 2026-01-27 | Millennium Management LLC | 2.7% |
| Schedule 13D/A, 2025-11-04 | Frazier Life Sciences Public Fund, L.P. | 8.6% |
| Schedule 13G/A, 2025-11-03 | Millennium Management LLC | 7.1% |
| Schedule 13G/A, 2025-08-28 | Carlyle Group Inc. | 4.9% |
| Schedule 13G/A, 2025-08-25 | Millennium Management LLC | 5.9% |
| Schedule 13D/A, 2025-08-20 | Frazier Life Sciences Public Fund, L.P. | 8.6% |
| Schedule 13G, 2025-08-13 | Millennium Management LLC | 5.3% |
Questions about who owns Phathom Pharmaceuticals, Inc.
Who owns Phathom Pharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Phathom Pharmaceuticals, Inc.: Frazier Life Sciences Public Fund, L.P. (7.4%, Schedule 13D/A, filed 2026-11-02) and Blackrock, Inc. (5.5%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Phathom Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Phathom Pharmaceuticals, Inc. on this page are Frazier Life Sciences Public Fund, L.P. (7.4%) and Blackrock, Inc. (5.5%).
When did Frazier Life Sciences Public Fund, L.P. buy into Phathom Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Frazier Life Sciences Public Fund, L.P. on this page is the Schedule 13D/A, filed 2025-08-20, reporting 8.6%; its latest, Schedule 13D/A filed 2026-11-02, reports 7.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Phathom Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Phathom Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phathom Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Phathom Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 5,957,449 shares (7.3% of shares outstanding), 66,718 held directly and 5,890,731 indirectly (Form 4, 2026-05-21).
- , the chief operating officer: 1,101,868.93 shares (1.4% of shares outstanding), 312,590 held directly and 789,278.93 indirectly (Form 4, 2025-03-03).
- , the chief executive and president: 373,315 shares (0.46% of shares outstanding) (Form 4, 2026-02-12).
- , the chief executive and president: 364,305.16 shares (0.45% of shares outstanding), 360,465 held directly and 3,840.16 indirectly (Form 4, 2025-01-23).
- , the chief financial officer and amp: 215,841 shares (0.27% of shares outstanding), 214,718 held directly and 1,123 indirectly (Form 4, 2026-10-08).
Shares outstanding: 81,291,520 as of 2026-10-27, from the company's latest SEC cover page.
How much has Phathom Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Phathom Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Phathom Pharmaceuticals, Inc. and the records around it.
Phathom Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Carlyle Group Inc. also filed stake reports on 7 other companies: SunPower Inc. (Aug 2026), Q32 Bio Inc. (Jul 2026), Medline Inc. (May 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026), Allogene Therapeutics, Inc. (Aug 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/phathom-pharmaceuticals